Praxis Gains After FDA Grants Breakthrough Therapy Designation To Elsunersen For SCN2A-DEE

Praxis Precision Medicines rose after the U.S. FDA granted Breakthrough Therapy Designation to Elsunersen for seizures associated with SCN2A Developmental and Epileptic Encephalopathy. The designation can accelerate development and review for a potentially important rare-disease treatment. The update is positive for the company, though the article does not provide approval data, pricing, or trial results.

Analysis

Praxis Precision Medicines rose after the U.S. FDA granted Breakthrough Therapy Designation to Elsunersen for seizures associated with SCN2A Developmental and Epileptic Encephalopathy. The designation can accelerate development and review for a potentially important rare-disease treatment. The update is positive for the company, though the article does not provide approval data, pricing, or trial results.